Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02LBZ
|
|||
| Drug Name |
PMID26560530-Compound-14
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. STEIN, Ross, L. CASE, April YEH, Li-An CUNY, Greg DUVAL, Eric
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H16N4O2S2
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)C2=CSC3=C2C(=O)N(C(=N3)SCC(=O)NN)C4=CC=CC=C4
|
|||
| InChI |
1S/C20H16N4O2S2/c21-23-16(25)12-28-20-22-18-17(15(11-27-18)13-7-3-1-4-8-13)19(26)24(20)14-9-5-2-6-10-14/h1-11H,12,21H2,(H,23,25)
|
|||
| InChIKey |
WLBUICQBNZXIDJ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.